Dr. Patnaik shares her perspectives on START’s pivotal role in the development of new cancer drugs
A Marathon and a Sprint The process of developing and bringing new medicines to patients in need is oftentimes lengthy and complex, which is why anything that can be done to expedite this process is critical for patients who are waiting for new treatment options. In the case of B6A, Seagen’s investigational antibody-drug conjugate (ADC),
